One month after $115M megaround, muscle disease-focused Dyne goes public with $233M IPO
After completing a financing megaround for $115 million just a little over a month ago, Dyne Therapeutics is ready to hit the Nasdaq on Thursday.
The biotech has raised $233 million for its public offering after pricing shares at $19 apiece, above its expected range of $16 to $18. That’s an offering that’s well-upsized — by about 33% — after Dyne initially filed its S-1 in late August, when it estimated only a $100 million raise. Dyne will trade under the ticker $DYN.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
